On 23 February 2023, the Board of Directors of Duopharma Biotech (“Board”) declared a second interim dividend of 1.8 sen per ordinary share in Duopharma Biotech (“Duopharma Biotech Share”) in respect of the financial year ended 31 December 2022 (“Second Interim Dividend 2022” or “Dividend”).
The shareholders of Duopharma Biotech had at the Company’s Extraordinary General Meeting held on 31 May 2018 approved, among others, the establishment of a dividend reinvestment plan that provides the shareholders of the Company with an option to elect to reinvest their cash dividend into new Duopharma Biotech Shares (“Reinvestment Option”) (“Dividend Reinvestment Plan”)
The Second Interim Dividend 2022 will be paid no later than 3 months from the date of declaration pursuant to Paragraph 8.26 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.
On 27 March 2023, AmInvestment Bank on behalf of the Board of Directors of Duopharma Biotech, announced that the issue price of the new Duopharma Biotech Shares to be issued pursuant to the DRP has been fixed (“Price-Fixing Date”) at RM1.35 per new Duopharma Biotech Shares. The dividend reinvestment plan, which provides Shareholders with an option to elect to reinvest in whole or in part their cash dividend into new Duopharma Biotech Shares, in lieu of receiving cash, shall apply to the entire portion of the Second Interim Dividend 2022.
The Issue Price is computed based on the five (5)-day volume weighted average market price (“VWAMP”) of RM1.5158 per Duopharma Biotech Share up to and including 24 March 2023, being the last trading day prior to the Price-Fixing Date after adjusting for the following:
The Notice of Election (including the Dividend Reinvestment Form) will be sent by electronic mail to shareholders of Duopharma Biotech who have registered their email addresses with Bursa Malaysia Depository Sdn Bhd (“Bursa Depository”) on 12 April 2023, after the Entitlement Date. For shareholders of Duopharma Biotech who have yet to register their email addresses with Bursa Depository, the hardcopy of the Notice of Election (including the Dividend Reinvestment Form) will be sent by ordinary post. A copy of the DRP Statement will be available at the Company’s website for shareholders to view and download on 12 April 2023. The election period for the DRP will close on 26 April 2023.
The entitlement date for the Second Interim Dividend 2022 and dividend reinvestment plan has been fixed on 10 April 2023.
The new Duopharma Biotech Shares arising from the DRP will be listed on the Main Market of Bursa Securities on 10 May 2023.